Amazon recently sent shock waves through healthcare when they announced their $3.9 billion acquisitionopens in a new tab or window of One Medical. This follows its 2018 acquisition of PillPack and 2019 Amazon Care launch. With $29 billion of venture investmentopens in a new tab or window into digital health in 2021, this may seem like just another headline -- but we feel this one is different.
In placing their bet on a primary care network that delivers a hybrid of in-person and virtual care, Amazon chose a path that positions it to be a front-runner in primary care innovation.
Read More: https://www.medpagetoday.com/opinion/second-opinions/100373?utm_source=Linkedin&utm_medium=Organic%20Social&utm_campaign=&utm_term=&utm_content=
Via: Medpage Today Via; Outset Medical Yesterday, in groundbreaking #kidneycare news, the American Heart Association issued a statement in support of home dialysis over in-center dialysis for patients with kidney and cardiovascular disease, citing cardiovascular co-morbidities and poor outcomes from thrice-weekly in-center hemodialysis, which is currently the most common therapy performed worldwide. Via: Outset Medical January Mendoza, BSN, RN, the Regional Director of Acute Dialysis at St. Francis Medical Center (SFMC) led a monumental transition when her hospital became the first in California to use a novel hemodialysis technology: #TabloDialysis. Via: Carlsmed A new peer-to-peer review video demonstrates how effective patient-specific implants can be in treating lumbar deformities with anterior/posterior fusion. Via: Mass Device Outset Medical (Nasdaq:OM) announced today that it has won a national contract with the U.S. Department of Veterans Affairs to sell its Tablo hemodialysis system into the department’s 106 VA hospitals. Via: Outset Medical Water quality depends on many “highly fluid” variables. It is the most important component in a safe and successful hemodialysis treatment, in any setting. Here we look at a few key impacts on water that are critical in protecting patients’ health. Via: NeuroNews Route 92 Medical has announced the publication of initial results from the SUMMIT NZ clinical trial—a single-arm, multicentre, prospective trial evaluating its proprietary Monopoint operating platform. Via: Bakersfield SAN MATEO, Calif., June 06, 2022 -- Route 92 Medical, Inc., a private medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the publication of initial results of the SUMMIT NZ clinical trial, a single-arm, multi-center, prospective trial evaluating the proprietary Monopoint operating platform. Results from the first 45 patients demonstrated that the Monopoint platform yielded an 80% first pass effect (FPE1) with primary use of the HiPoint™ 88 (.088in ID) catheter, a super-bore catheter designed to consistently reach the proximal middle cerebral artery (MCA). The Route 92 HiPoint 88 aspiration catheter successfully reached the proximal MCA (M1 segment) in 100% of the cases attempted. The results were published in the Journal of NeuroInterventional Surgery online2. Digital Care for Chronic Musculoskeletal Pain: 10,000 Participant Longitudinal Cohort Study6/3/2022
Via: Hinge Health Chronic musculoskeletal pain has a vast global prevalence and economic burden. Conservative therapies are universally recommended but require patient engagement and self-management to be effective. This study aimed to evaluate the efficacy of a 12-week digital care program (DCP) in a large population of patients with chronic knee and back pain. Silk Road Medical Announces Expanded Medicare Coverage for TCAR in Standard Surgical Risk Patients6/2/2022
Via: GlobalNewswire SUNNYVALE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that the Centers for Medicare and Medicaid Services (CMS), through collaboration with the Society of Vascular Surgery’s Patient Safety Organization (SVS PSO) and their Vascular Quality Initiative (VQI), has expanded coverage for TCAR to include standard surgical risk patients within the VQI’s TCAR Surveillance Project (TSP). This decision is effective immediately and comes on the heels of the recent Food and Drug Administration (FDA) approval for expanded indications for the ENROUTE® Transcarotid Stent System to include patients at high risk and standard risk for adverse events from carotid endarterectomy (CEA). |
Archives
October 2023
|